kidney cancer

Advertisement
Charlotte RobinsonNephrology Times | November 24, 2024
Patients with CKD may experience a higher risk of cancer, so researchers examined whether this relationship may be causal.
Read More
Charlotte RobinsonNephrology Times | July 25, 2024
In a phase 2 study, adding tivozanib to nivolumab did not show a benefit for renal cell carcinoma treatment.
Charlotte RobinsonNephrology Times | July 16, 2024
The FDA granted Fast Track designation to ADI-270 for treating metastatic or advanced clear cell renal cell carcinoma.
Pavlos Msaouel, MD, PhDOncology | February 12, 2024
What does the data and overall understanding of VEGF-TKIs tell us about which patients are optimal candidates for tivozanib?
Victoria SochaDiabetes and Hypertension | February 5, 2024
Hypertension is a common adverse effect associated with the use of tyrosine kinase inhibitors (TKIs), such as axitinib. ...
Patrick DalyOncology | September 12, 2023
In ESMO Open, Enrique Grande, MD, and collaborating researchers published findings from the IMMUNOSUN trial on the ...
Victoria SochaNephrology Times | February 5, 2024
Major organizations have issued guidelines for the treatment and management of kidney cancer that favor nephron-sparing ...
Rebecca AraujoOncology | May 14, 2021
This week on DocWire, editors spoke with Giovanni Di Napoli, President of Medtronic Gastrointestinal, about GI Genius, ...
Rebecca AraujoOncology | April 16, 2021
This week, findings from a clinical trial of children with high-risk Hodgkin lymphoma found the anti-CD30 antibody drug ...
Rebecca AraujoOncology | April 14, 2021
New research from the Memorial Sloan Kettering Cancer Center and the Gustave Roussy Institute found that some patients ...
Victoria SochaASCO 2019 | October 31, 2019
Renal cell carcinoma (RCC) is the most common histologic type of urologic cancer. Worldwide, the age-standardized rate ...
Victoria SochaASCO 2019 | October 24, 2019
Several therapeutic combinations of immune-oncology (IO) plus vascular endothelial growth factor (VEGF) regimens have ...
Victoria SochaASCO 2019 | April 25, 2023
Immune Checkpoint Therapy plus Cytoreductive Surgery in mRCC ...
Victoria SochaASCO 2019 | April 25, 2023
Immune Checkpoint Inhibitor Response in Patients with mRCC ...
Victoria SochaASCO 2019 | October 14, 2019
Costs of episodes of care in metastatic renal cell carcinoma (mRCC) vary by therapy and treatment decisions have ...
Victoria SochaASCO 2019 | October 10, 2019
Ipilimumab plus nivolumab is a first-line combination treatment option in patients with metastatic renal cell carcinoma ...
Victoria SochaASCO 2019 | October 7, 2019
Nivolumab plus ipilimumab was proven superior to sunitinib in objective response rate and overall survival in patients ...
Victoria SochaOncology | October 2, 2019
Clinicians have used comprehensive genomic profiling to inform treatment selection in patients with metastatic renal ...
Kaitlyn D’OnofrioOncology | September 22, 2023
A study published in The Lancet Oncology found that pegilodecakin in combination with anti-PD-1 monoclonal antibody ...
DocWire News EditorsNon-Small Cell Lung Cancer | September 20, 2023
A new study has found that patients with non-small cell lung cancer (NSCLC) and kidney cancer may benefit from ...
Advertisement
Advertisement
Advertisement
Latest News

March 18, 2025